Expand AKTX Menu
AKTX MENU

AKTX Stock Posts


AKTX stock declines -15.5% in premarket,

Premarket Decliner

AKTX Akari Therapeutics PLC - American Depositary Shares5.80+0.68+13.3%

Premarket:4.90-0.90 (-15.5%)

Akari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA Splicing

Globe NewswireMon, 20-Apr 8:35 AM
AKTX stock increases 35.9% in premarket,

Premarket Gainer

AKTX Akari Therapeutics PLC Ads2.06+0.03+1.5%

Premarket:2.80+0.74 (+35.9%)

Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting

Globe NewswireMon, 2-Dec 8:30 AM
AKTX stock increases 46.1% in premarket,

Premarket Gainer

AKTX Akari Therapeutics PLC Ads1.80+0.03+1.9%

Premarket:2.63+0.83 (+46.1%)

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

Globe NewswireWed, 14-Aug 8:00 AM
AKTX stock increases 21.8% in premarket,

Premarket Gainer

AKTX Akari Therapeutics PLC ADR3.35+0.23+7.4%

Premarket:4.08+0.73 (+21.8%)

Akari Therapeutics Announces Positive Initial Phase II Clinical Data in Orphan Skin Disease Bullous Pemphigoid

Globe NewswireTue, 23-Apr 8:31 AM
Load Earlier Posts
Market Data Delayed 15 Minutes